|1.||Tanaka, Ryo: 2 articles (01/2014 - 04/2010)|
|2.||Morimoto, Sachio: 2 articles (04/2010 - 01/2005)|
|3.||Sakato, Mitsuo: 2 articles (01/2005 - 09/2003)|
|4.||Hamabe, Lina: 1 article (01/2014)|
|5.||Fukushima, Ryuji: 1 article (01/2014)|
|6.||Yoshiyuki, Rieko: 1 article (01/2014)|
|7.||Kawamura, Keisuke: 1 article (01/2014)|
|8.||Shimizu, Miki: 1 article (01/2014)|
|9.||Fukayama, Toshiharu: 1 article (01/2014)|
|10.||Kim, Soo-Min: 1 article (01/2014)|
09/01/2003 - "Thus, SCH00013 was beneficial for the survival of cardiomyopathic hamsters, suggesting that this agent is a possible candidate for the treatment of chronic heart failure."
01/01/2005 - "These results strongly suggested that SCH00013 is a novel Ca(2+) sensitizer that elicits a positive inotropic and no chronotropic effect in heart failure, probably through enhancing the Frank-Starling mechanism."
01/01/2005 - "SCH00013 elicited a positive inotropic effect at more than 0.3 and 1 mg/kg, i.v. in normal and heart failure dogs, respectively, with no chronotropic action. "
01/01/2005 - "We investigated the effects of the agent SCH00013 on Ca(2+)-induced force generation in rabbit skinned cardiac muscle fibers and in vivo cardiac function in high-pacing-induced heart failure dogs. "
01/01/2005 - "SCH00013, a novel Ca(2+) sensitizer with positive inotropic and no chronotropic action in heart failure."
|2.||Left Ventricular Dysfunction
|5.||Hypotension (Low Blood Pressure)
|1.||Drug Therapy (Chemotherapy)